Cancer Genetics pays $12M for Australian CRO vivoPharm

The deal sees CGI boost its immuno-oncology offerings.

U.S. oncology specialist Cancer Genetics will pay $12 million to buy out Australian contract research organization vivoPharm as it looks to bolster its offerings.

Cancer Genetics (CGI) says the deal will boost its position “as a premier leader for oncology discovery, in vivo and in vitro drug development and early phase clinical trial testing for biotechnology and pharmaceutical companies.”

It buys into vivoPharm, a firm that has spent 10 years offering discovery and preclinical services to support drug development, target validation and biomarker analysis, with a big focus on immuno-oncology.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The CRO currently works with more than 40 biopharmas across five continents, in more than 55 studies and trials. It’s led by Ralf Brandt, who will be “fully integrated as the flagship in CGI’s discovery services offering,” according to its new owner, serving as the president of this unit.

The deal closed this week, and sees its 32 staffers subsumed into CGI. The price paid, $12 million, includes $1.2 million in cash, with the remaining 90% in the form of shares of CGI common stock. The company has also signed an equity financing deal for up to $16 million to fund the takeover.

“The acquisition is expected to be immediately accretive, adding both revenue and income,” CGI said in a statement.

“The combination of capabilities is expected to create considerable business opportunities in both pre-clinical studies and immuno-oncology clinical trials, to further accelerate CGI’s strategy to be the premier partner of choice for oncology innovation and development from bench to bedside.”

Suggested Articles

The trial hit its primary endpoint by the time of an interim analysis, enabling Chi-Med to stop the study and start work on a filing for approval.

The anticipated fundraising haul will bankroll development of a pipeline of RAS programs up to the completion of IND-enabling studies.

As GlaxoSmithKline looks to start a 23andMe-partnered test this year, the Big Pharma is increasingly looking to tech for its R&D.